News
Mission drives innovation, and innovation improves quality of life
News
-
ASH 2023 | TargetRx to highlight advances of TGRX-678 in CML2023-11-03 Views:37
The 65th Annual Meeting of the American Society of Hematology (ASH) will be held in San Diego, USA, from Decemb ...
-
TargetRx to present PhaseⅠclinical data of TGRX-326 at the 2023 ASCO Annual Meeting2023-05-05 Views:139
TargetRx will present clinical data from PhaseⅠstudy of TGRX-326 in Advanced ALK-positive non-small cell lung canc ... -
TargetRx was awarded the "2021 China's Top 100 Pharmaceutical R&D Strength Series"2021-09-26 Views:203
"2021 China s Top 100 Pharmaceutical R&D Strength Series " is evaluated by the YAOZHI com, the committee of China Pharmaceutical R&D-Summit Organizing Committee and China Pharmaceutical, referring to the R&D-related data... -
TargetRx announces dosing of first subject in phase I clinical trial of TGRX-326, a next-generation ALK inhibitor for non-small cell lung cancer2021-07-01 Views:341
Recently, Shenzhen TargetRx Inc (hereinafter referred to as TargetRx) announced that the first subject has been dosed with the ALK ROS1 inhibitor TGRX-326, a Class 1 innovative new drug for treatment of non-small cell lung cancer, in (First-in-Human) ... -
TargetRx announces dosing of first subject in first-in-human phase I clinical trial of TGRX-678, an allosteric BCR-ABL inhibitor with novel mechanism against chronic myelogenous leukemia2021-06-24 Views:383
Recently, Shenzhen TargetRx Inc (hereinafter referred to as TargetRx), a leader in small molecule targeted drugs, announced that the first subject has been dosed in the first-in-human clinical trial of its allosteric Bcr-Abl inhibitor TGRX-678 with a new... -
Clinical Trial Recruitment | Patient Recruitment for Clinical Study of TargetRx's third-generation ALK inhibitor TGRX-326 for NSCLC2021-03-15 Views:164
A phase I dose-escalation and expansion clinical trial to evaluate the safety, tolerability, pharmacokinetics and preliminary effectiveness of TGRX-326 in patients with ALK-positive or ROS1-positive advanced non-small cell lung cancer...
Tel: +86-0755-86934300
3rd Floor, Building A1, Kexing Science Park, No. 15 Keyuan Rd., Nanshan District, Shenzhen, China
E-mail: 